The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...